PDF(Pubmed)
Abstract：
Purpose: The aim of this study was to determine the odds ratio of anaplastic large-cell lymphoma in late seroma formation. Methods: In a PubMed search, 415 articles were found using the terms \"breast implant AND seroma\" (n = 232), \"breast implant AND effusion\" (n = 42), and \"anaplastic large cell lymphoma AND breast (n = 141). Sixty-seven abstracts were read, and 27 full articles were reviewed. Results: Three articles reported the incidence of late seroma in breast implants, with a total of 75 seromas out of 48,211 implants (0.16%). One article reported 48 cases of non-Hodgkin lymphoma from 43,537 implants (0.11%). Another article reported that 11 patients had anaplastic large-cell lymphoma among 389 primary lymphoma of the breast (2.83%). Two articles reported 143 seromas out of 236 anaplastic large-cell lymphomas (60.59%). The risk of anaplastic large-cell lymphoma was significantly higher in the patients having late seroma than those without seroma (odds ratio = 998.93; 95% confidence interval, 768.90-1297.78; P < .001). The incidence of anaplastic large-cell lymphoma in seroma was calculated by dividing the number of anaplastic large cell lymphomas with seroma (n = 143) by total seroma (N = 11,843), which resulted in an incidence of 1.21%. The expected incidence of anaplastic large-cell lymphoma in seroma was 1.21%. Conclusion: If late seroma develops after breast implant insertion, ultrasonography-guided aspiration should be performed, with enzyme-linked-immunosorbent serologic assay for CD30.
摘要：
目的：本研究的目的是确定间变性大细胞淋巴瘤在晚期血清瘤形成中的优势比。方法：在PubMed搜索中，发现415篇文章使用术语“乳房植入物和血清肿”(n=232)，“乳房植入和积液”(n=42)，和“间变性大细胞淋巴瘤和乳腺（n=141）。阅读了67份摘要，并回顾了27篇完整文章。结果：三篇文章报道了乳房植入物中晚期血清肿的发生率，在48,211个植入物中总共有75个血清瘤（0.16％）。一篇文章报道了43,537个植入物中的48例非霍奇金淋巴瘤（0.11％）。另一篇文章报道，在389例原发性乳腺淋巴瘤中，有11例患者有间变性大细胞淋巴瘤（2.83％）。两篇文章报道了236例间变性大细胞淋巴瘤中的143例血清瘤(60.59%)。晚期血清肿患者发生间变性大细胞淋巴瘤的风险明显高于无血清肿患者(比值比=998.93;95%置信区间,768.90-1297.78；P<.001）。血清瘤中的间变性大细胞淋巴瘤的发生率是通过将具有血清瘤的间变性大细胞淋巴瘤（n=143）的数量除以总血清瘤（N=11,843）来计算的，导致1.21%的发病率。血清间变性大细胞淋巴瘤的预期发病率为1.21%。结论：如果乳房植入物插入后出现晚期血清肿，应进行超声引导下的抽吸，CD30的酶联免疫吸附血清学测定。
